Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.49 |
| ▸ | GRPR | P30550 | 4/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857406 | 0.88 | CXCR4 (0.58) | IL23RGRPRCXCR4 | |
| SCHEMBL18857392 | 0.82 | CXCR4 (0.64) | GRPRCXCR4MC4R | |
| SCHEMBL18862462 | 0.78 | REN (0.66) | RENGRPR | |
| SCHEMBL18854322 | 0.77 | IL23R (0.60) | RENIL23RGRPR | |
| SCHEMBL18857385 | 0.76 | GRPR (0.56) | GRPRCXCR4 | |
| SCHEMBL18854274 | 0.75 | GRPR (0.53) | GRPRCXCR4 | |
| SCHEMBL18857750 | 0.75 | IL23R (0.57) | IL23RGRPR | |
| SCHEMBL18862332 | 0.73 | REN (0.69) | REN | |
| SCHEMBL29360000 | 0.73 | IL23R (0.51) | RENIL23RCXCR4 | |
| SCHEMBL18857383 | 0.73 | CXCR4 (0.52) | GRPRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | REN 2795/4885IL23R 333/4885GRPR 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.